TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00875563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith(R) Fenestrated AAA Endovascular Graft
Description: The Zenith(R) Fenestrated AAA Endovascular Graft with the H\&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
Study: NCT02104427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-0054 combined with G-CSF
Study: NCT05826210

Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy was performed in all patients with or without SO.

Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy was performed in all patients with or without SO.
Study: NCT01102712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTVA System
Description: Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
Study: NCT02277327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plans of Action and Care Transitions
Description: Subjects randomized to the intervention will participate in action planning and care transitions (if hospitalized during the study period)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine Care
Description: Subjects randomized to the control group will continue to receive routine care within the medical home program
Study: NCT03722082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing Cognitive Reserve
Description: The intervention is aimed at improving cognitive reserve in offsprings of patients diagnosed with schizophrenia or bipolar disorder. The program is composed of 12 sessions of 60 minutes and will be adapted according the three different age groups (6-12) (13-18) (18-25). Each group will include between 6-to-8 offsprings and conducted by 4 experienced neuropsychologists in both children and adults. The sessions are the following:

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Support intervention
Description: The support group will schedule meetings with the participants in order to talk about their daily life with the possibility to talk about the difficulties they encounter.
Study: NCT01841970

Intervention type: DEVICE
Group type: OTHER
Intervention: HET Bipolar System
Description: The HET Bipolar System is used to treat hemorrhoids by bipolar ligation of the superior hemorrhoidal blood supply.
Study: NCT01425736

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy :Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab and Chemotherapy
Description: Nimotuzumab treatment:(200mg/w,18weeks );~Chemotherapy treatment:(Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)Nimotuzumab treatment:(200mg/w,18weeks );
Study: NCT03861780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Project X 26ml
Description: Application of antiseptic drug to the inguinal and abdomen areas of the subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Project X 5.1ml
Description: Application of antiseptic drug to the inguinal and abdomen areas of the subjects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevantics Maxi Swabstick
Description: Application of antiseptic drug to the inguinal and abdomen areas of the subjects
Study: NCT03278496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Housing plus Counseling
Description: Participants receive 3 months of abstinence-contingent program-supported rent payment in community recovery housing. They also receive intensive outpatient counseling (both individual and group) focused on relapse prevention skills training, goal setting, employment seeking and recreational activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Referral
Description: Participants are referred to an outpatient program of their choosing with an appointment made for them.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Housing Only
Description: Participant may receive up to 3 months of abstinence-contingent rent payment in community recovery housing but is not invited to participate in intensive counseling.
Study: NCT00652912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: ODT, 1 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klonopin Wafers
Description: ODT, 1 mg
Study: NCT02182401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA
Description: Days 3-8 and days 25-30

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA
Description: Days 15-30

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Days 1, 7, 23 and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: Days 1, 7, 23 and 29
Study: NCT02475434

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cream Supplement group
Description: Infants in the intervention arm will receive the cream supplement in addition to the standard regimen.
Study: NCT04302402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin has been demonstrated in multiple IBS studies, through a postulated effect on the gut microbiota, to improve the symptoms of pain and bloating, which are important symptoms in subjects with functional dyspepsia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar looking placebo
Study: NCT02219685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet administered orally once daily
Study: NCT04789525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic training with high protein diet
Description: High-intensity aerobic training was given with 50 to 70 % of the maximum heart rate. the intervention started with 10 mins of warm-up exercise through stretching of upper and lower limb muscles. Subsequent to stretching, the subjects were asked to do 30 mins of exercises; consisting of 20 mins on the treadmill and 10 mins of cycle ergometer at 50 to 70 % of MHR, then with 10 mins of cool down.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic training with high protein diet
Description: High-intensity aerobic training was given with 50 to 70 % of the maximum heart rate. the intervention started with 10 mins of warm-up exercise through stretching of upper and lower limb muscles. Subsequent to stretching, the subjects were asked to do 30 mins of exercises; consisting of 20 mins on the treadmill and 10 mins of cycle ergometer at 50 to 70 % of MHR, then with 10 mins of cool down.
Study: NCT01848106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegnivacogin/anivamersen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bivalirudin
Study: NCT00821275

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interventional radiological or surgical management
Description: Uterine artery embolization will be done for the patients who enroll into UAE group and desire for future pregancy and reserving uterus.Myomectomy will be performed for the patients who enroll into SURGERY group and desire for future pregancy and reserving uterus.Hysterectomy will be done for the patients who enroll into SURGERY group and don't desire for reserving uterus and/or future pregnancy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interventional radiological or surgical management
Description: Uterine artery embolization will be done for the patients who enroll into UAE group and desire for future pregancy and reserving uterus.Myomectomy will be performed for the patients who enroll into SURGERY group and desire for future pregancy and reserving uterus.Hysterectomy will be done for the patients who enroll into SURGERY group and don't desire for reserving uterus and/or future pregnancy.
Study: NCT01854749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1 combined with cisplatin
Study: NCT03618446

Intervention type: OTHER
Intervention: The presence of a pelvic fracture

Intervention type: OTHER
Intervention: The presence of a pelvic fracture
Study: NCT02130947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT03225170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Affirmation (SA)
Description: Clients will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. They will then be asked to write about the item that is most important to them and why it may be important to them.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Clients will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. The control group will rank the list and be asked to write about the 9th ranked item and why it might be important to someone else.
Study: NCT00480571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-1020
Description: BL-1020 Low Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL 1020 High Dose
Description: BL 1020 High Dose
Study: NCT02564276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Study: NCT01610037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 110/50 µg will be supplied as capsules in blister packs for once daily inhalation using the Novartis Concept1 SDDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 µg will be supplied as capsules in blister packs for once daily inhalation using the HandiHaler SDDPI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to QVA149A and Tiotropium will be supplied in the appropriate capsule in blister packs for use in either the Novartis Concept1 SDDPI or the HandiHaler SDDPI
Study: NCT01048541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Catheter - SpeediCath Compact Male
Description: Compact catheter for intermittent catheterisation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpeediCath
Description: Catheter for intermittent catheterisation
Study: NCT03641261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic patient education program
Description: WebIchtyose is a specific therapeutic patient education program for patients with hereditary Ichthyosis targeting the problems of each patient by means of a personalized follow-up and a constant interaction between the patient and the educational team
Study: NCT00627497

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-Level Posterior Decompression
Description: The single level posterior decompression is a posterior surgical procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIAM Spinal Stabilization
Description: The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIAM Spinal Stabilization
Description: The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fusion
Description: Posterolateral Interbody Fusion
Study: NCT03522116

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00379145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabectedin
Study: NCT00980824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Description: Six sessions brief CBT.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Referral to NHS services appropriate to patient's needs
Study: NCT04113941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuronox
Description: intradetrusor injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intradetrusor injection
Study: NCT02955303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TECH: Tablet Enhancement of Cognition and Health
Description: cognitive training using touchscreen tablet gaming applications
Study: NCT04569175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D Flair sequence
Description: Optimized 3D FLAIR sequence before and 4 hours after the usual care MRI (with contrast product). All patients will have the same intervention as each patient is its own control
Study: NCT03682068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab IV (intravenous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin + Gemcitabine
Description: Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin + Gemcitabine
Description: Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin + Gemcitabine
Description: Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin + Gemcitabine
Description: Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin + Gemcitabine
Description: Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin + Gemcitabine
Description: Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
Study: NCT03339817

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Polysomnography
Description: During polysomnographia and functional pulmonary testing, signs of diaphragmatic dysfunction responsible for respiratory disorders will be searched.
Study: NCT03193047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bempedoic acid 180mg
Description: Daily bempedoic acid 180mg tablet in addition to monthly PCSK9i (evolocumab) background therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Daily matching placebo tablet in addition to monthly PCSK9i (evolocumab) background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evolocumab
Description: Monthly PCSK9i (evolocumab) background therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: evolocumab
Description: Monthly PCSK9i (evolocumab) background therapy
Study: NCT02871609

Intervention type: OTHER
Intervention: Stent examination, urinary analysis, USSQ questionnaire
Study: NCT01999439

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eosinophilic Esophagitis with Dysphagia
Description: An upper endoscopy with biopsy at the time of diagnosis(which is a standard procedure to diagnose eosinophilic esophagitis. This will be done with sedation or general anesthesia, also a standard procedure. At the time of the anesthesia a small amount of blood will be drawn to measure markers of inflammation and fibrosis. This procedure will take approximately 45 minutes to complete. This endoscopy with biopsy will be repeated in 6 months.~Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eosinophilic Esophagitis with Dysphagia
Description: Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete.
Study: NCT01429844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus therapy was started immediately after transplantation with a continuous intravenous infusion of 0.01-0.03 mg/kg/d. After extubation, the mode of delivery was switched to oral administration (b.i.d.) with doses of 0.05-0.3 mg/kg/d. Tacrolimus doses were adjusted to trough levels. Target C0 (trough) levels were 10-15 ng/ml for the first 3 months after transplantation and 8-12 ng/ml thereafter with dose adjustments according to patient outcome.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Cyclosporine therapy was started immediately after transplantation with a continuous intravenous infusion of 1-3 mg/kg/d. After extubation the mode of delivery was switched to oral administration (b.i.d. or t.i.d.) with doses of 4-18 mg/kg/d. Cyclosporine doses were adjusted to C0 or C2 levels according to local practice. Target trough levels were 200 - 300 ng/ml for the first 3 months after transplantation and 150 - 200 ng/ml thereafter.
Study: NCT02221648

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomization to receive either the study drug or the placebo group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AbobotulinumtoxinA Treatment
Description: Subjects receive intervention injections with the study drug arbobotulinumtoxinA.
Study: NCT05739604

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample analysis
Description: The concentrations of AAs and related compounds were determined by liquid chromatography/mass spectrometry (LC/MS)

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample analysis
Description: The concentrations of AAs and related compounds were determined by liquid chromatography/mass spectrometry (LC/MS)
Study: NCT00371956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raloxifene
Description: 60mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tab 1 daily
Study: NCT03569397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Patients will be administered music therapy during the operation.
Study: NCT03701880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine is pacemaker current I(f) inhibitor thereby slowing heart rates without exhibiting negative inotropic effect on the myocardium or altering ventricular action potential

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine is pacemaker current I(f) inhibitor thereby slowing heart rates without exhibiting negative inotropic effect on the myocardium or altering ventricular action potential

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: Bisoprolol is beta-blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Bisoprolol is beta-blocker
Study: NCT04211597

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No scar prevention or treatment.
Study: NCT03639246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-S6-500
Description: AVB-S6-500 is experimental drug
Study: NCT04211597

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silicone gel
Description: Dermatix® (Dermatix® Ultra, Menarini Asia-Pacific, Taiwan FDA approved)
Study: NCT03639246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-S6-500
Description: AVB-S6-500 is experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-S6-500
Description: AVB-S6-500 is experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-S6-500
Description: AVB-S6-500 is experimental drug
Study: NCT04211597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silicone gel
Description: Dermatix® (Dermatix® Ultra, Menarini Asia-Pacific, Taiwan FDA approved)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: microencapsulated polysaccharide and oligopeptide-1(Me-EGF) 40 mcg & 5 mcg
Description: 4ml (40 mcg) of Me-EGF spray will be given by the operating physician prior to wound closure, followed by daily application of 5 mcg until day +5 after delivery. Starting from day +14, participants will receive FDA approved Silicone gel to be applied to the Cesarean wound twice a day for two months. Participants also receive routine post-partum care as usual.
Study: NCT01261117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral ibuprofen
Description: oral or iv ibuprofen in 10, 5 and 5 mg/kg/day with 24 hr intervals
Study: NCT03639246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Pac)
Description: Paclitaxel is active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Pac)
Description: Paclitaxel is active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel (Pac)
Description: Paclitaxel is active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: PLD is active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: PLD is active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: PLD is active comparator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo comparator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT02364388

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Imagio IUS
Description: Imagio diagnostic gray-scale ultrasound

Intervention type: DEVICE
Group type: OTHER
Intervention: Imagio IUS
Description: Imagio diagnostic gray-scale ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Imagio OA/US
Description: Diagnostic opto-acoustic +gray-scale ultrasound

Intervention type: DEVICE
Group type: OTHER
Intervention: Imagio OA/US
Description: Diagnostic opto-acoustic +gray-scale ultrasound